• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Publication
Peer-Reviewed
Evidence-Based OncologyJanuary 2021
Volume 27
Issue 1

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.

eAPPENDIX Clinical and Economic Burden of Intravenous Paclitaxel
Articles in this issue
Evidence-Based Oncology
ASH 2020: Clinical Updates
ASH 2020: COVID-19 and Hematology
ASH 2020: COVID-19 and Hematology
ASH 2020: CAR T-Cell Therapy Updates
ASH 2020: CAR T-Cell Therapy Updates
ASH 2020: The Next Wave
ASH 2020: The Next Wave
Evidence-Based Oncology
2020 SABCS: Topics in Precision Oncology
Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines
Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
evidence-based oncology
Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
Evidence-Based Oncology
Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer
Evidence-Based Oncology
Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer
Related Videos
Michael Hassett, MD
Michael Hassett, MD
Adam Brufsky, MD, PhD
Danielle Roman, PharmD, BCOP, Allegheny Health Network
Michael Hassett, MD, MPH
Related Content
AI and digital health are redefining what’s possible in breast cancer treatment. | Image Credit: @PajarosVolando-adobe.stock.jpeg

5 AI and Digital Health Advances Transforming Breast Cancer Care and Research

November 14th 2025
Article

AI and digital tools are reshaping breast cancer care—from screening and trials to remote monitoring and lifestyle support.

Read More

Age-Related Disparities in ADC Treatment Rates in Breast Cancer: Tabby Khan, MD

Age-Related Disparities in ADC Treatment Rates in Breast Cancer: Tabby Khan, MD

October 31st 2025
Podcast

A new analysis from Komodo Health pinpointed significant disparities by age and insurance in antibody-drug conjugate (ADC) treatment rates for metastatic breast cancer.

Listen

AI may help optimize breast cancer clinical trial enrollment rates and trial design. | Image Credit: @Pixel-Shot-AdobeStock.jpeg

Low Trial Enrollment, Racial Disparities Limit Breast Cancer Treatment Innovation

October 24th 2025
Article

Artificial intelligence models may advance clinical trial design and enrollment to improve trial success and patient outcomes.

Read More

The Evolution of AI Models in Mammography With Robert Nishikawa, PhD

The Evolution of AI Models in Mammography With Robert Nishikawa, PhD

October 23rd 2025
Podcast

AI-powered mammography is enhancing breast cancer screening and early detection through cutting-edge radiology insights.

Listen

FDA approved imlunestrant, and oral estrogen-receptor degrader to treat advanced breast cancer. | Image Credit: @aznan - stock.adobe.com .jpeg

FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer

September 25th 2025
Article

FDA approved the monotherapy for estrogen receptor (ER)–positive and HER2-negative metastatic breast cancer.

Read More

Adjuvant therapies may mitigate risk of recurrence in wome with early-stage breast cancer.| Image Credit: @smolaw11-Adobestick.jpeg

Adjuvant Therapies May Mitigate Risk of Recurrence in Women With Early-Stage Breast Cancer

September 19th 2025
Article

The Oncotype DX 21-gene recurrence score helps guide adjuvant therapy in women with early-stage breast cancer and low genomic risk.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.